Enzalutamide

Phase 3

Roche Holding AG (RHHBY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

RHHBYPhase 3$316.4B

Enzalutamide Phase 3 Est. Readout

Enzalutamide• Prostatic Neoplasms, Castration-Resistant49

Q2 2027~QConfirmed

CT.gov

00%

Q2 '27

RHHBYPhase 2$316.4B

Enzalutamide Phase 2 Est. Readout

Enzalutamide• Prostatic Neoplasms, Castration-Resistant100

Q2 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Prostatic Neoplasms, Castration-Resistant

View Full Landscape

Drug Information

Target Indication

Prostatic Neoplasms, Castration-Resistant

Clinical Trial

NCT03016312

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

5-Fluorouracil (5-FU)Phase 3

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Leucovorin calciumPhase 3

Colorectal Cancer

Nonbiologic DMARDs of investigator's choicePhase 3

Rheumatoid Arthritis

Tocilizumab 162 mgPhase 3

Rheumatoid Arthritis

Optional Endocrine Therapy of Investigator's ChoicePhase 3

Metastatic Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts